Hematologic Malignancy
Acute Promyelocytic Leukemia
CI-CAN-00008681APL · APMLExplore in graph →
Hematologic14 active trials2 approved drugs16 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008681APL · APMLExplore in graph →
Clinical trials
89 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07504458 | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia(QUATRO-APL) | recruiting | Phase 3 | 150 | Quetzal TherapeuticsINDUSTRY | 5 | Sep 23, 2026 | clinicaltrials |
| NCT07597941 | Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | not yet recruiting | Phase 2 / Phase 3 | 20 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jun 30, 2026 |
| clinicaltrials |
| NCT02688140 | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia(TUD-APOLLO-064) | completed | Phase 3 | 133 | Technische Universität DresdenOTHER | 5 | May 29, 2026 | clinicaltrials |
| NCT07503730 | Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).(EARLY-RIF APL) | recruiting | Phase 3 | 224 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02339740 | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | active not recruiting | Phase 3 | 158 | Children's Oncology GroupNETWORK | 6 | Feb 18, 2026 | clinicaltrials |
| NCT07296445 | A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)(LATITUDE) | not yet recruiting | Phase 3 | 120 | SDK Therapeutics, Inc.INDUSTRY | 0 | Dec 29, 2025 | clinicaltrials |
| NCT06544109 | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients(Ven APL) | enrolling by invitation | Phase 2 / Phase 3 | 98 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT00866918 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia | completed | Phase 3 | 106 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT02899169 | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)(APL16) | unknown | Phase 3 | 110 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT04175587 | Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL(RIF) | unknown | Phase 3 | 109 | Peking University People's HospitalOTHER | 0 | Nov 29, 2019 | clinicaltrials |
| NCT01226303 | Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | unknown | Phase 3 | 300 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 1 | Jan 26, 2017 | clinicaltrials |
| NCT00003934 | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | completed | Phase 3 | 420 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00517712 | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia(IAPLSG04) | unknown | Phase 2 / Phase 3 | 400 | Christian Medical College, Vellore, IndiaOTHER | 1 | Aug 17, 2007 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials